Loading…
Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial
In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 pa...
Saved in:
Published in: | Circulation (New York, N.Y.) N.Y.), 1985-11, Vol.72 (5), p.1059-1063 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3 |
---|---|
cites | |
container_end_page | 1063 |
container_issue | 5 |
container_start_page | 1059 |
container_title | Circulation (New York, N.Y.) |
container_volume | 72 |
creator | MOK, C. K BOEY, J WANG, R CHAN, T. K CHEUNG, K. L LEE, P. K CHOW, J NG, R. P TSE, T. F |
description | In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 patients followed for 395.6 patient-years, the thromboembolic rate was significantly less in the warfarin group (warfarin vs dipyridamole-aspirin, p less than .005; warfarin vs pentoxifylline-aspirin, p less than .05). Subgroup analysis disclosed that, in patients with isolated mitral valve replacement, warfarin was superior to both of the PSTs with respect to the prevention of thromboembolism (warfarin vs dipyridamole-aspirin, p = .005; warfarin vs pentoxifylline-aspirin, p less than .05). Furthermore, a significant number of our patients could not tolerate the antiplatelet agents. However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis. |
doi_str_mv | 10.1161/01.CIR.72.5.1059 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_76372603</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>76372603</sourcerecordid><originalsourceid>FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3</originalsourceid><addsrcrecordid>eNpFkU1r3DAQhkVpSDdp770UdCi92ZVky7J7K0s_AoFCSelRyNKIqMiWK3mXbP5P_2dmkyU9CDF6n_nQvIS85azmvOMfGa-3Vz9rJWpZcyaHF2TDpWirVjbDS7JhjA2VaoR4RS5K-YNh1yh5Ts6bfhha1m7Iv98me5PDTPeQy65QF5ZDDs5MKUJlyhKOmpkdXWBe013whxjD_F_yKdP1FuiSYY9ESDNNHqNU8HUNlt6CySvdm7gHBHOaxgR4YijTJ2oeyQXsGlDO2CdN4R4ctdgkWBPpmoOJr8mZN7HAm9N9SX59_XKz_V5d__h2tf18XdmWdWvlrLXQK8uB9d7JsR_aQQpvWyWlZR7akSkLzWCGRjg_KtPbzvfSCeuU4NY3l-TDU12c6u8OyqqnUCzEaGZIu6IVrk90rEGQPYEWxy8ZvF5ymEw-aM700RnNuEZntBJa6qMzmPLuVHs3TuCeE05WoP7-pJuCH_e4DBvKM9a3HZopmwe_U50G</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>76372603</pqid></control><display><type>article</type><title>Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial</title><source>Free E-Journal (出版社公開部分のみ)</source><creator>MOK, C. K ; BOEY, J ; WANG, R ; CHAN, T. K ; CHEUNG, K. L ; LEE, P. K ; CHOW, J ; NG, R. P ; TSE, T. F</creator><creatorcontrib>MOK, C. K ; BOEY, J ; WANG, R ; CHAN, T. K ; CHEUNG, K. L ; LEE, P. K ; CHOW, J ; NG, R. P ; TSE, T. F</creatorcontrib><description>In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 patients followed for 395.6 patient-years, the thromboembolic rate was significantly less in the warfarin group (warfarin vs dipyridamole-aspirin, p less than .005; warfarin vs pentoxifylline-aspirin, p less than .05). Subgroup analysis disclosed that, in patients with isolated mitral valve replacement, warfarin was superior to both of the PSTs with respect to the prevention of thromboembolism (warfarin vs dipyridamole-aspirin, p = .005; warfarin vs pentoxifylline-aspirin, p less than .05). Furthermore, a significant number of our patients could not tolerate the antiplatelet agents. However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis.</description><identifier>ISSN: 0009-7322</identifier><identifier>EISSN: 1524-4539</identifier><identifier>DOI: 10.1161/01.CIR.72.5.1059</identifier><identifier>PMID: 3899404</identifier><identifier>CODEN: CIRCAZ</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott Williams & Wilkins</publisher><subject>Adult ; Aspirin - therapeutic use ; Biological and medical sciences ; Blood. Blood coagulation. Reticuloendothelial system ; Clinical Trials as Topic ; Dipyridamole - therapeutic use ; Drug Combinations ; Female ; Heart Valve Prosthesis ; Humans ; Male ; Medical sciences ; Middle Aged ; Pentoxifylline - therapeutic use ; Pharmacology. Drug treatments ; Postoperative Complications - drug therapy ; Postoperative Complications - prevention & control ; Prospective Studies ; Random Allocation ; Theobromine - analogs & derivatives ; Thromboembolism - drug therapy ; Thromboembolism - prevention & control ; Warfarin - therapeutic use</subject><ispartof>Circulation (New York, N.Y.), 1985-11, Vol.72 (5), p.1059-1063</ispartof><rights>1986 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=8460095$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/3899404$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>MOK, C. K</creatorcontrib><creatorcontrib>BOEY, J</creatorcontrib><creatorcontrib>WANG, R</creatorcontrib><creatorcontrib>CHAN, T. K</creatorcontrib><creatorcontrib>CHEUNG, K. L</creatorcontrib><creatorcontrib>LEE, P. K</creatorcontrib><creatorcontrib>CHOW, J</creatorcontrib><creatorcontrib>NG, R. P</creatorcontrib><creatorcontrib>TSE, T. F</creatorcontrib><title>Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial</title><title>Circulation (New York, N.Y.)</title><addtitle>Circulation</addtitle><description>In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 patients followed for 395.6 patient-years, the thromboembolic rate was significantly less in the warfarin group (warfarin vs dipyridamole-aspirin, p less than .005; warfarin vs pentoxifylline-aspirin, p less than .05). Subgroup analysis disclosed that, in patients with isolated mitral valve replacement, warfarin was superior to both of the PSTs with respect to the prevention of thromboembolism (warfarin vs dipyridamole-aspirin, p = .005; warfarin vs pentoxifylline-aspirin, p less than .05). Furthermore, a significant number of our patients could not tolerate the antiplatelet agents. However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis.</description><subject>Adult</subject><subject>Aspirin - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Blood. Blood coagulation. Reticuloendothelial system</subject><subject>Clinical Trials as Topic</subject><subject>Dipyridamole - therapeutic use</subject><subject>Drug Combinations</subject><subject>Female</subject><subject>Heart Valve Prosthesis</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pentoxifylline - therapeutic use</subject><subject>Pharmacology. Drug treatments</subject><subject>Postoperative Complications - drug therapy</subject><subject>Postoperative Complications - prevention & control</subject><subject>Prospective Studies</subject><subject>Random Allocation</subject><subject>Theobromine - analogs & derivatives</subject><subject>Thromboembolism - drug therapy</subject><subject>Thromboembolism - prevention & control</subject><subject>Warfarin - therapeutic use</subject><issn>0009-7322</issn><issn>1524-4539</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1985</creationdate><recordtype>article</recordtype><recordid>eNpFkU1r3DAQhkVpSDdp770UdCi92ZVky7J7K0s_AoFCSelRyNKIqMiWK3mXbP5P_2dmkyU9CDF6n_nQvIS85azmvOMfGa-3Vz9rJWpZcyaHF2TDpWirVjbDS7JhjA2VaoR4RS5K-YNh1yh5Ts6bfhha1m7Iv98me5PDTPeQy65QF5ZDDs5MKUJlyhKOmpkdXWBe013whxjD_F_yKdP1FuiSYY9ESDNNHqNU8HUNlt6CySvdm7gHBHOaxgR4YijTJ2oeyQXsGlDO2CdN4R4ctdgkWBPpmoOJr8mZN7HAm9N9SX59_XKz_V5d__h2tf18XdmWdWvlrLXQK8uB9d7JsR_aQQpvWyWlZR7akSkLzWCGRjg_KtPbzvfSCeuU4NY3l-TDU12c6u8OyqqnUCzEaGZIu6IVrk90rEGQPYEWxy8ZvF5ymEw-aM700RnNuEZntBJa6qMzmPLuVHs3TuCeE05WoP7-pJuCH_e4DBvKM9a3HZopmwe_U50G</recordid><startdate>198511</startdate><enddate>198511</enddate><creator>MOK, C. K</creator><creator>BOEY, J</creator><creator>WANG, R</creator><creator>CHAN, T. K</creator><creator>CHEUNG, K. L</creator><creator>LEE, P. K</creator><creator>CHOW, J</creator><creator>NG, R. P</creator><creator>TSE, T. F</creator><general>Lippincott Williams & Wilkins</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>198511</creationdate><title>Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial</title><author>MOK, C. K ; BOEY, J ; WANG, R ; CHAN, T. K ; CHEUNG, K. L ; LEE, P. K ; CHOW, J ; NG, R. P ; TSE, T. F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1985</creationdate><topic>Adult</topic><topic>Aspirin - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Blood. Blood coagulation. Reticuloendothelial system</topic><topic>Clinical Trials as Topic</topic><topic>Dipyridamole - therapeutic use</topic><topic>Drug Combinations</topic><topic>Female</topic><topic>Heart Valve Prosthesis</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pentoxifylline - therapeutic use</topic><topic>Pharmacology. Drug treatments</topic><topic>Postoperative Complications - drug therapy</topic><topic>Postoperative Complications - prevention & control</topic><topic>Prospective Studies</topic><topic>Random Allocation</topic><topic>Theobromine - analogs & derivatives</topic><topic>Thromboembolism - drug therapy</topic><topic>Thromboembolism - prevention & control</topic><topic>Warfarin - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>MOK, C. K</creatorcontrib><creatorcontrib>BOEY, J</creatorcontrib><creatorcontrib>WANG, R</creatorcontrib><creatorcontrib>CHAN, T. K</creatorcontrib><creatorcontrib>CHEUNG, K. L</creatorcontrib><creatorcontrib>LEE, P. K</creatorcontrib><creatorcontrib>CHOW, J</creatorcontrib><creatorcontrib>NG, R. P</creatorcontrib><creatorcontrib>TSE, T. F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Circulation (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>MOK, C. K</au><au>BOEY, J</au><au>WANG, R</au><au>CHAN, T. K</au><au>CHEUNG, K. L</au><au>LEE, P. K</au><au>CHOW, J</au><au>NG, R. P</au><au>TSE, T. F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial</atitle><jtitle>Circulation (New York, N.Y.)</jtitle><addtitle>Circulation</addtitle><date>1985-11</date><risdate>1985</risdate><volume>72</volume><issue>5</issue><spage>1059</spage><epage>1063</epage><pages>1059-1063</pages><issn>0009-7322</issn><eissn>1524-4539</eissn><coden>CIRCAZ</coden><abstract>In a prospective, randomized, parallel study, two regimens of platelet-suppressant therapy (PST)--dipyridamole-aspirin and pentoxifylline-aspirin--were compared with standard oral anticoagulation with warfarin in the prevention of prosthetic heart valve thromboembolism. In the entire group of 254 patients followed for 395.6 patient-years, the thromboembolic rate was significantly less in the warfarin group (warfarin vs dipyridamole-aspirin, p less than .005; warfarin vs pentoxifylline-aspirin, p less than .05). Subgroup analysis disclosed that, in patients with isolated mitral valve replacement, warfarin was superior to both of the PSTs with respect to the prevention of thromboembolism (warfarin vs dipyridamole-aspirin, p = .005; warfarin vs pentoxifylline-aspirin, p less than .05). Furthermore, a significant number of our patients could not tolerate the antiplatelet agents. However, in the rare situation in which repeated significant bleeding occurs despite careful adjustment of the dosage of warfarin, PST may be an acceptable alternate method of thromboembolism prophylaxis.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott Williams & Wilkins</pub><pmid>3899404</pmid><doi>10.1161/01.CIR.72.5.1059</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0009-7322 |
ispartof | Circulation (New York, N.Y.), 1985-11, Vol.72 (5), p.1059-1063 |
issn | 0009-7322 1524-4539 |
language | eng |
recordid | cdi_proquest_miscellaneous_76372603 |
source | Free E-Journal (出版社公開部分のみ) |
subjects | Adult Aspirin - therapeutic use Biological and medical sciences Blood. Blood coagulation. Reticuloendothelial system Clinical Trials as Topic Dipyridamole - therapeutic use Drug Combinations Female Heart Valve Prosthesis Humans Male Medical sciences Middle Aged Pentoxifylline - therapeutic use Pharmacology. Drug treatments Postoperative Complications - drug therapy Postoperative Complications - prevention & control Prospective Studies Random Allocation Theobromine - analogs & derivatives Thromboembolism - drug therapy Thromboembolism - prevention & control Warfarin - therapeutic use |
title | Warfarin versus dipyridamole-aspirin and pentoxifylline-aspirin for the prevention of prosthetic heart valve thromboembolism: a prospective randomized clinical trial |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T01%3A38%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Warfarin%20versus%20dipyridamole-aspirin%20and%20pentoxifylline-aspirin%20for%20the%20prevention%20of%20prosthetic%20heart%20valve%20thromboembolism:%20a%20prospective%20randomized%20clinical%20trial&rft.jtitle=Circulation%20(New%20York,%20N.Y.)&rft.au=MOK,%20C.%20K&rft.date=1985-11&rft.volume=72&rft.issue=5&rft.spage=1059&rft.epage=1063&rft.pages=1059-1063&rft.issn=0009-7322&rft.eissn=1524-4539&rft.coden=CIRCAZ&rft_id=info:doi/10.1161/01.CIR.72.5.1059&rft_dat=%3Cproquest_cross%3E76372603%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c406t-dccce87c1e08fd5b894952fc4755c0fe4b07ce39a932dfb7a8c6f85d2cd721cf3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=76372603&rft_id=info:pmid/3899404&rfr_iscdi=true |